|
Synonyms: CSL-324 | CSL324
Compound class:
Antibody
Comment: Anumigilimab (CSL-324) is a clinical stage monoclonal antibody that targets colony stimulating factor 3 receptor (CSF3R). It was developed by CSL Behring for potential efficacy in inflammatory/autoimmune diseases. The heavy and light chain peptide sequences for anumigilimab are claimed in patent WO2012171057A1 [1].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use  |
| Anumigilimab (CSL-324) is in early stage clinical development. Study NCT04519424 to determine anumigilimab's ability to reduce inflammation in patients with severe COVID-19 was withdrawn (for business reasons), before any patients were recruited. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT03972280 | Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis | Phase 1 Interventional | CSL Behring | ||
| NCT04570267 | Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects | Phase 1 Interventional | CSL Behring | ||
